Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.

Megumi Kurosawa; Masayuki Sekine; Manako Yamaguchi; Risa Kudo; Sharon J. B. Hanley; Megumi Hara; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Sayaka Ikeda; Asami Yagi; Takayuki Enomoto

doi:10.1111/cas.15282

Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.

Megumi Kurosawa, Masayuki Sekine^* (Corresponding Author), Manako Yamaguchi, Risa Kudo, Sharon J. B. Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

3 Downloads (Pure)

Abstract

In Japan, public funding for HPV vaccination began in 2010 for girls aged 13-16 years (birth cohort years 1994-1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long-term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25-26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993-1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92-109 months). The HPV high-risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross-protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long-term 9-year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.

Original language	English
Pages (from-to)	1435-1440
Number of pages	6
Journal	Cancer Science
Volume	113
Issue number	4
Early online date	14 Feb 2022
DOIs	https://doi.org/10.1111/cas.15282
Publication status	Published - 1 Apr 2022

Bibliographical note

ACKNOWLEDGEMENTS
We would like to thank Ms. Yuka Watanabe, Ms. Sachiko Ono, Ms. Anna Ishida, and the administrator of Niigata city for their support in conducting the survey

Keywords

Adult
Female
Humans
Japan/epidemiology
cervical cancer
HPV infection
HPV vaccine
Early Detection of Cancer
Vaccination
Japan
*Papillomavirus Infections/diagnosis/epidemiology/prevention & control
*Papillomavirus Vaccines/therapeutic use
*Uterine Cervical Neoplasms/epidemiology/prevention & control
Human papillomavirus 16
Human papillomavirus 18
long-term effectiveness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.15282Licence: CC BY-NC

Kurosawa_etal_CS_Long_Term_Effectiveness_VoR
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 386 KBLicence: CC BY-NC

Cite this

@article{e83793bb89fe49b7b69a8044c3bcb1c5,

title = "Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.",

abstract = "In Japan, public funding for HPV vaccination began in 2010 for girls aged 13-16 years (birth cohort years 1994-1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long-term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25-26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993-1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92-109 months). The HPV high-risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross-protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long-term 9-year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.",

keywords = "Adult, Female, Humans, Japan/epidemiology, cervical cancer, HPV infection, HPV vaccine, Early Detection of Cancer, Vaccination, Japan, *Papillomavirus Infections/diagnosis/epidemiology/prevention & control, *Papillomavirus Vaccines/therapeutic use, *Uterine Cervical Neoplasms/epidemiology/prevention & control, Human papillomavirus 16, Human papillomavirus 18, long-term effectiveness",

author = "Megumi Kurosawa and Masayuki Sekine and Manako Yamaguchi and Risa Kudo and Hanley, {Sharon J. B.} and Megumi Hara and Sosuke Adachi and Yutaka Ueda and Etsuko Miyagi and Sayaka Ikeda and Asami Yagi and Takayuki Enomoto",

note = "ACKNOWLEDGEMENTS We would like to thank Ms. Yuka Watanabe, Ms. Sachiko Ono, Ms. Anna Ishida, and the administrator of Niigata city for their support in conducting the survey",

year = "2022",

month = apr,

day = "1",

doi = "10.1111/cas.15282",

language = "English",

volume = "113",

pages = "1435--1440",

journal = "Cancer Science",

issn = "1349-7006",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women

T2 - Real-world data.

AU - Kurosawa, Megumi

AU - Sekine, Masayuki

AU - Yamaguchi, Manako

AU - Kudo, Risa

AU - Hanley, Sharon J. B.

AU - Hara, Megumi

AU - Adachi, Sosuke

AU - Ueda, Yutaka

AU - Miyagi, Etsuko

AU - Ikeda, Sayaka

AU - Yagi, Asami

AU - Enomoto, Takayuki

N1 - ACKNOWLEDGEMENTS We would like to thank Ms. Yuka Watanabe, Ms. Sachiko Ono, Ms. Anna Ishida, and the administrator of Niigata city for their support in conducting the survey

PY - 2022/4/1

Y1 - 2022/4/1

N2 - In Japan, public funding for HPV vaccination began in 2010 for girls aged 13-16 years (birth cohort years 1994-1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long-term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25-26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993-1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92-109 months). The HPV high-risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross-protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long-term 9-year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.

AB - In Japan, public funding for HPV vaccination began in 2010 for girls aged 13-16 years (birth cohort years 1994-1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long-term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25-26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993-1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92-109 months). The HPV high-risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross-protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long-term 9-year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.

KW - Adult

KW - Female

KW - Humans

KW - Japan/epidemiology

KW - cervical cancer

KW - HPV infection

KW - HPV vaccine

KW - Early Detection of Cancer

KW - Vaccination

KW - Japan

KW - Papillomavirus Infections/diagnosis/epidemiology/prevention & control

KW - Papillomavirus Vaccines/therapeutic use

KW - Uterine Cervical Neoplasms/epidemiology/prevention & control

KW - Human papillomavirus 16

KW - Human papillomavirus 18

KW - long-term effectiveness

U2 - 10.1111/cas.15282

DO - 10.1111/cas.15282

M3 - Article

SN - 1349-7006

VL - 113

SP - 1435

EP - 1440

JO - Cancer Science

JF - Cancer Science

IS - 4

ER -

Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this